From the years 2001-2004 to 2017-March 2020, the prevalence of adults with CKD who are aware of their diagnosis increased from approximately 7.5% to 11.5%, respectively.
The proportion of adults who are aware of their diagnosis has steadily been increasing within the last 19 years. From the years 2001-2004 to 2017-March 2020, the prevalence of adults with CKD who are aware of their diagnosis increased from approximately 7.5% to 11.5%, respectively.
The survey consists of a standardized in-home interview and a physical examination with blood and urine collected at a mobile examination center (MEC). Here, we examined data from 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, 2017-March 2020 NHANES. The estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for calibrated creatinine (Levey et al., 2009). Serum creatinine was calibrated for 1999-2000 and 2005-2006 participants; no correction was required for calibrated serum creatinine in participants in the 2001-2002, 2003-2004, 2007-2008, 2009-2010, 2011-2012, 2013-2014, and 2015-2016 surveys (Selvin et al., 2007). Albuminuria was defined by urinary albumin-to-creatinine ratio ≥30 mg/g; moderate albuminuria ranges between 30 and 299 mg/g and severe albuminuria is ≥300 mg/g; pregnant women were excluded. For comparisons across the 18-year period 1999-2016, albuminuria was corrected in 1999-2006 to account for differences in the instrumentation and method for urine creatinine starting in 2007. The prevalence of CKD is likely overestimated by single measurements of albuminuria and kidney function (eGFR). In clinical practice, CKD is defined by persistent albuminuria or reduced kidney function for ≥3 months.
The proportion of adults with CKD who know they have it.
NCHS
Public
NHANES
No
National
Noninstitutionalized U.S. residents aged 18+ years old.
Stage 1, eGFR ≥ 90 ml/min/1.73 m² and presence of single albuminuria; Stage 2, eGFR 60-89 ml/min/1.73 m² and presence of single albuminuria; Stage 3, eGFR 30-59 ml/min/1.73 m²; Stage 4, 15-29 ml/min/1.73 m²; Stage 5, excluded
Estimated using CKD-EPI equation for calibrated creatinine: eGFR=141 x [min(calibrated serum creatinine in mg/dL) /κ, 1)]α x [max(calibrated serum creatinine in mg/dL/κ, 1)]κ x 0.993age x (1.018 if female) x (1.159 if NH Black) κ = 0.7 if female, and 0.9 if male α = -0.329 if female, and -0.411 if male
Urinary albumin-to-creatinine ratios of 30-299 mg/g (microalbuminuria) and >300 mg/g (macroalbuminuria); pregnant/menstruating women excluded
Examination/Laboratory
Appropriate NHANES survey weights must be used for all analyses